Siegel RL, Miller KD, Fuchs HE, Jemal A. Most cancers statistics, 2022. CA Most cancers J Clin. 2022;72:7–33.
Carried out JZ, Fang SH. Younger-onset colorectal most cancers: a overview. World J Gastrointest Oncol. 2021;13:856–66.
Argiles G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon most cancers: ESMO Scientific Observe Tips for prognosis, therapy and follow-up. Ann Oncol. 2020;31:1291–305.
Overman MJ, Ernstoff MS, Morse MA. The place we stand with immunotherapy in colorectal most cancers: poor mismatch restore, proficient mismatch restore, and toxicity administration. Am Soc Clin Oncol Educ E book. 2018;38:239–47.
Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, et al. Precise 10-year survival after hepatic resection of colorectal liver metastases: what elements preclude remedy? Surgical procedure. 2018;163:1238–44.
Yu J, Inexperienced MD, Li S, Solar Y, Journey SN, Choi JE, et al. Liver metastasis restrains immunotherapy efficacy by way of macrophage-mediated T cell elimination. Nat Med. 2021;27:152–64.
Engeland CE, Bell JC. Introduction to oncolytic virotherapy. Strategies Mol Biol. 2020;2058:1–6.
Kim Y, Clements DR, Sterea AM, Jang HW, Gujar SA, Lee PW. Dendritic cells in oncolytic virus-based anti-cancer remedy. Viruses. 2015;7:6506–25.
Berkey SE, Thorne SH, Bartlett DL. Oncolytic virotherapy and the tumor microenvironment. Adv Exp Med Biol. 2017;1036:157–72.
Harrington Ok, Freeman DJ, Kelly B, Harper J, Soria JC. Optimizing oncolytic virotherapy in most cancers therapy. Nat Rev Drug Discov. 2019;18:689–706.
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2018;174:1031–2.
Crupi MJF, Taha Z, Janssen TJA, Petryk J, Boulton S, Alluqmani N, et al. Oncolytic virus pushed T-cell-based mixture immunotherapy platform for colorectal most cancers. Entrance Immunol. 2022;13:1029269.
Luo Q, Track H, Deng X, Li J, Jian W, Zhao J, et al. A triple-regulated oncolytic adenovirus carrying microRNA-143 displays potent antitumor efficacy in colorectal most cancers. Mol Ther Oncolytics. 2020;16:219–29.
Ren Y, Miao JM, Wang YY, Fan Z, Kong XB, Yang L, et al. Oncolytic viruses mixed with immune checkpoint remedy for colorectal most cancers is a promising therapy possibility. Entrance Immunol. 2022;13:961796.
Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Part 1 examine of intravenous administration of the chimeric adenovirus enadenotucirev in sufferers present process main tumor resection. J Immunother Most cancers. 2017;5:71.
Monge C, Xie C, Myojin Y, Coffman Ok, Hrones DM, Wang S, et al. Part I/II examine of PexaVec together with immune checkpoint inhibition in refractory metastatic colorectal most cancers. J Immunother Most cancers. 2023;11, https://doi.org/10.1136/jitc-2022-005640.
Hu H, Zhang S, Cai L, Duan H, Li Y, Yang J, et al. A novel cocktail remedy primarily based on quintuplet mixture of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 x CCL19 leads to enhanced antitumor efficacy. Virol J. 2022;19:74.
Sethumadhavan S, Barth M, Spaapen RM, Schmidt C, Trowitzsch S, Tampe R. Viral immune evasins impression antigen presentation by allele-specific trapping of MHC I on the peptide-loading complicated. Sci Rep. 2022;12:1516.
Zhao Q, Zhang W, Ning Z, Zhuang X, Lu H, Liang J, et al. A novel oncolytic herpes simplex virus kind 2 has potent anti-tumor exercise. PLoS ONE. 2014;9:e93103.
Zhang W, Hu X, Liang J, Zhu Y, Zeng B, Feng L, et al. oHSV2 can goal murine colon carcinoma by altering the immune standing of the tumor microenvironment and inducing antitumor immunity. Mol Ther Oncolytics. 2020;16:158–71.
Edin S, Gylling B, Li X, Stenberg A, Lofgren-Burstrom A, Zingmark C, et al. Opposing roles by KRAS and BRAF mutation on immune cell infiltration in colorectal most cancers—potential implications for immunotherapy. Br J Most cancers. 2023. https://doi.org/10.1038/s41416-023-02483-9.
Sacconi A, Muti P, Pulito C, Urbani G, Allegretti M, Pellini R, et al. Immunosignatures related to TP53 standing and co-mutations classify prognostically head and neck most cancers sufferers. Mol Most cancers. 2023;22:192.
Toshida Ok, Itoh S, Iseda N, Izumi T, Yoshiya S, Toshima T, et al. Impression of TP53-induced glycolysis and apoptosis regulator on malignant exercise and resistance to ferroptosis in intrahepatic cholangiocarcinoma. Most cancers Sci. 2023. https://doi.org/10.1111/cas.15981.
Gajic ZZ, Deshpande A, Legut M, Imielinski M, Sanjana NE. Recurrent somatic mutations as predictors of immunotherapy response. Nat Commun. 2022;13:3938.
Zhang C, Wang Ok, Lin J, Wang H. Non-small-cell lung most cancers sufferers harboring TP53/KRAS co-mutation may gain advantage from a PD-L1 inhibitor. Future Oncol. 2022;18:3031–41.
Yang Z, Solar JK, Lee MM, Chan MK. Restoration of p53 exercise by way of intracellular protein supply sensitizes triple unfavorable breast most cancers to anti-PD-1 immunotherapy. J Immunother Most cancers. 2022;10. https://doi.org/10.1136/jitc-2022-005068.
Albers S, Allen EC, Bharti N, Davyt M, Joshi D, Perez-Garcia CG, et al. Engineered tRNAs suppress nonsense mutations in cells and in vivo. Nature. 2023;618:842–8.
Cheng J, Novati G, Pan J, Bycroft C, Zemgulyte A, Applebaum T, et al. Correct proteome-wide missense variant impact prediction with AlphaMissense. Science. 2023;381:eadg7492.
Srivastava AK, Wang Y, Huang R, Skinner C, Thompson T, Pollard L, et al. Human genome assembly 2016 : Houston, TX, USA. 28 February – 2 March 2016. Hum Genomics. 2016;10:12.
Westcott PMK, Sacks NJ, Schenkel JM, Ely ZA, Smith O, Hauck H, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal most cancers. Nat Most cancers. 2021;2:1071–85.
Middha S, Zhang L, Nafa Ok, Jayakumaran G, Wong D, Kim HR, et al. Dependable Pan-cancer microsatellite instability evaluation by utilizing focused next-generation sequencing information. JCO Summary Oncol. 2017. https://doi.org/10.1200/PO.17.00084.
Cho IJ, Ki SH, Brooks C third, Kim SG. Function of hepatitis B virus X repression of C/EBPbeta exercise within the down-regulation of glutathione S-transferase A2 gene: implications in different part II detoxifying enzyme expression. Xenobiotica. 2009;39:182–92.
Yamashita M, Honda A, Ogura A, Kashiwabara S, Fukami Ok, Baba T. Lowered fertility of mouse epididymal sperm missing Prss21/Tesp5 is rescued by sperm publicity to uterine microenvironment. Genes Cells. 2008;13:1001–13.
Jakovljevic A, Nikolic N, Carkic J, Beljic-Ivanovic Ok, Soldatovic I, Miletic M, et al. Affiliation of polymorphisms in TNF-alpha, IL-1beta, GSTM and GSTT genes with apical periodontitis: is there a hyperlink with herpesviral an infection? Int Endod J. 2020;53:895–904.
Johnson N, De Ieso P, Migliorini G, Orr N, Broderick P, Catovsky D, et al. Cytochrome P450 allele CYP3A7*1C associates with hostile outcomes in persistent lymphocytic leukemia, breast, and lung most cancers. Most cancers Res. 2016;76:1485–93.
Rozario T, DeSimone DW. The extracellular matrix in growth and morphogenesis: a dynamic view. Dev Biol. 2010;341:126–40.
Alsisi A, Eftimie R, Trucu D. Nonlocal multiscale modelling of tumour-oncolytic viruses interactions inside a heterogeneous fibrous/non-fibrous extracellular matrix. Math Biosci Eng. 2022;19:6157–85.
Lee M, Chang Y, Ahmadinejad N, Johnson-Agbakwu C, Bailey C, Liu L. COVID-19 mortality is related to pre-existing impaired innate immunity in well being situations. PeerJ. 2022;10:e13227.
Saalbach A, Tremel J, Herbert D, Schwede Ok, Wandel E, Schirmer C, et al. Anti-inflammatory motion of keratinocyte-derived vaspin: relevance for the pathogenesis of psoriasis. Am J Pathol. 2016;186:639–51.
Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New Engl J Med. 2015;372:2509–20.
O’Neil BH, Wallmark JM, Lorente D, Elez E, Raimbourg J, Gomez-Roca C, et al. Security and antitumor exercise of the anti-PD-1 antibody pembrolizumab in sufferers with superior colorectal carcinoma. PLoS ONE. 2017;12:e0189848.
Moretto R, Rossini D, Catteau A, Antoniotti C, Giordano M, Boccaccino A, et al. Dissecting tumor lymphocyte infiltration to foretell profit from immune-checkpoint inhibitors in metastatic colorectal most cancers: classes from the AtezoT RIBE examine. J Immunother Most cancers. 2023;11. https://doi.org/10.1136/jitc-2022-006633.
Szeto C, Lobos CA, Nguyen AT, Gras S. TCR Recognition of peptide-MHC-I: rule makers and breakers. Int J Mol Sci. 2020;22. https://doi.org/10.3390/ijms22010068.
Li R, Wang J, Li X, Liang Y, Jiang Y, Zhang Y, et al. T-cell receptor sequencing reveals hepatocellular carcinoma immune traits in keeping with Barcelona Clinic liver most cancers levels inside liver tissue and peripheral blood. Most cancers Sci. 2023. https://doi.org/10.1111/cas.16013.
Chen YT, Hsu HC, Lee YS, Liu H, Tan BC, Chin CY, et al. Longitudinal high-throughput sequencing of the T-cell receptor repertoire reveals dynamic change and prognostic significance of peripheral blood TCR variety in metastatic colorectal most cancers throughout chemotherapy. Entrance Immunol. 2021;12:743448.
Schumacher TN, Scheper W, Kvistborg P. Most cancers neoantigens. Annu Rev Immunol. 2019;37:173–200.
Gerritsen B, Pandit A. The reminiscence of a killer T cell: fashions of CD8(+) T cell differentiation. Immunol Cell Biol. 2016;94:236–41.
Ando M, Ito M, Srirat T, Kondo T, Yoshimura A. Reminiscence T cell, exhaustion, and tumor immunity. Immunol Med. 2020;43:1–9.
Moon JJ, Chu HH, Pepper M, McSorley SJ, Jameson SC, Kedl RM, et al. Naive CD4(+) T cell frequency varies for various epitopes and predicts repertoire variety and response magnitude. Immunity. 2007;27:203–13.
Kunzli M, Masopust D. CD4(+) T cell reminiscence. Nat Immunol. 2023;24:903–14.
Li J, Liang W, Li Ok, Jiao X, Ai Ok, Zhang Y, et al. ZAP70 activation is an early occasion of T cell immunity that concerned within the anti-bacterial adaptive immune response of Nile tilapia. Dev Comp Immunol. 2021;124:104177.
Mishra S, Liao W, Liu Y, Yang M, Ma C, Wu H, et al. TGF-beta and Eomes management the homeostasis of CD8+ regulatory T cells. J Exp Med. 2021;218. https://doi.org/10.1084/jem.20200030.
Boto P, Csuth TI, Szatmari I. RUNX3-mediated immune cell growth and maturation. Crit Rev Immunol. 2018;38:63–78.
Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH. A novel transcription issue, T-bet, directs Th1 lineage dedication. Cell. 2000;100:655–69.
Diaz LA Jr., Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal most cancers (KEYNOTE-177): remaining evaluation of a randomised, open-label, part 3 examine. Lancet Oncol. 2022;23:659–70.
Wang D, Zhang H, Xiang T, Wang G. Scientific utility of adaptive immune remedy in mss colorectal most cancers sufferers. Entrance Immunol. 2021;12:762341.
Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in sufferers with superior gastric or colorectal most cancers: an open-label, dose-escalation, and dose-expansion part Ib trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38:2053–61.
Fakih M, Sandhu J, Lim D, Li X, Li S, Wang C. Regorafenib, ipilimumab, and nivolumab for sufferers with microsatellite steady colorectal most cancers and illness development with prior chemotherapy: a part 1 nonrandomized scientific trial. JAMA Oncol. 2023;9:627–34.
Fakih M, Raghav KPS, Chang DZ, Larson T, Cohn AL, Huyck TK, et al. Regorafenib plus nivolumab in sufferers with mismatch repair-proficient/microsatellite steady metastatic colorectal most cancers: a single-arm, open-label, multicentre part 2 examine. EClinicalMedicine. 2023;58:101917.
Kawazoe A, Xu RH, Garcia-Alfonso P, Passhak M, Teng HW, Shergill A, et al. Lenvatinib Plus Pembrolizumab Versus Normal of Take care of Beforehand Handled Metastatic Colorectal Most cancers: Remaining Evaluation of the Randomized, Open-Label, Part III LEAP-017 Research. J Clin Oncol. 2024. https://doi.org/10.1200/JCO.23.02736.
Wang C, Lu N, Yan L, Li Y. The efficacy and security evaluation of oncolytic virotherapies within the therapy of superior melanoma: a scientific overview and meta-analysis. Virol J. 2023;20:252.
Li Z, Feiyue Z, Gaofeng L, Haifeng L. Lung most cancers and oncolytic virotherapy–enemy’s enemy. Transl Oncol. 2023;27:101563.
Wang Z, Solar P, Li Z, Xiao S. Scientific advances and future instructions of oncolytic virotherapy for head and neck most cancers. Cancers. 2023;15. https://doi.org/10.3390/cancers15215291.
Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves sturdy response charge in sufferers with superior melanoma. J Clin Oncol. 2015;33:2780–8.
Zhang B, Huang J, Tang J, Hu S, Luo S, Luo Z, et al. Intratumoral OH2, an oncolytic herpes simplex virus 2, in sufferers with superior stable tumors: a multicenter, part I/II scientific trial. J Immunother Most cancers. 2021;9. https://doi.org/10.1136/jitc-2020-002224.
Zhang L, Pakmehr SA, Shahhosseini R, Hariri M, Fakhrioliaei A, Karkon Shayan F, et al. Oncolytic viruses enhance most cancers immunotherapy by reprogramming stable tumor microenvironment. Med Oncol. 2023;41:8.
Ma J, Ramachandran M, Jin C, Quijano-Rubio C, Martikainen M, Yu D, et al. Characterization of virus-mediated immunogenic most cancers cell loss of life and the implications for oncolytic virus-based immunotherapy of most cancers. Cell Demise Dis. 2020;11:48.
Packiriswamy N, Upreti D, Zhou Y, Khan R, Miller A, Diaz RM, et al. Oncolytic measles virus remedy enhances tumor antigen-specific T-cell responses in sufferers with a number of myeloma. Leukemia. 2020;34:3310–22.
DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369–82.
Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X, et al. Polarization of tumor-associated macrophages by nanoparticle-loaded Escherichia coli mixed with immunogenic cell loss of life for most cancers immunotherapy. Nano Lett. 2021;21:4231–40.
Denton NL, Chen CY, Scott TR, Cripe TP. Tumor-associated macrophages in oncolytic virotherapy: pal or foe? Biomedicines. 2016;4. https://doi.org/10.3390/biomedicines4030013.
Zheng C, Zheng L, Yoo JK, Guo H, Zhang Y, Guo X, et al. Panorama of infiltrating T cells in liver most cancers revealed by single-cell sequencing. Cell. 2017;169:1342–56.e1316.
Cha E, Klinger M, Hou Y, Cummings C, Ribas A, Faham M, et al. Improved survival with T cell clonotype stability after anti-CTLA-4 therapy in most cancers sufferers. Sci Transl Med. 2014;6:238ra270.
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
Snyder A, Nathanson T, Funt SA, Ahuja A, Buros Novik J, Hellmann MD, et al. Contribution of systemic and somatic elements to scientific response and resistance to PD-L1 blockade in urothelial most cancers: an exploratory multi-omic evaluation. PLoS Med. 2017;14:e1002309.
Dong LQ, Peng LH, Ma LJ, Liu DB, Zhang S, Luo SZ, et al. Heterogeneous immunogenomic options and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72:896–908.
Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: present expertise and scientific functions. J Hematol Oncol. 2022;15:131.
Zhang Q, Luo J, Wu S, Si H, Gao C, Xu W, et al. Prognostic and predictive impression of circulating tumor DNA in sufferers with superior cancers handled with immune checkpoint blockade. Most cancers Discov. 2020;10:1842–53.
Razavi P, Dickler MN, Shah PD, Toy W, Brown DN, Gained HH, et al. Alterations in PTEN and ESR1 promote scientific resistance to alpelisib plus aromatase inhibitors. Nat Most cancers. 2020;1:382–93.
Ling AL, Solomon IH, Landivar AM, Nakashima H, Woods JK, Santos A, et al. Scientific trial hyperlinks oncolytic immunoactivation to survival in glioblastoma. Nature. 2023;623:157–66.
Ponce S, Cedres S, Ricordel C, Isambert N, Viteri S, Herrera-Juarez M, et al. ONCOS-102 plus pemetrexed and platinum chemotherapy in malignant pleural mesothelioma: a randomized part 2 examine investigating scientific outcomes and the tumor microenvironment. J Immunother Most cancers. 2023;11. https://doi.org/10.1136/jitc-2023-007552.
Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, et al. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a part 1/2 trial. Nat Med. 2023;29:1370–8.
Heo J, Liang JD, Kim CW, Woo HY, Shih IL, Su TH, et al. Security and dose escalation of the focused oncolytic adenovirus OBP-301 for refractory superior liver most cancers: Part I scientific trial. Mol Ther. 2023;31:2077–88.
Keshavarz M, Mohammad Miri S, Behboudi E, Arjeini Y, Dianat-Moghadam H, Ghaemi A. Oncolytic virus supply modulated immune responses towards most cancers remedy: challenges and views. Int Immunopharmacol. 2022;108:108882.
Moon EK, Wang LS, Bekdache Ok, Lynn RC, Lo A, Thorne SH, et al. Intra-tumoral supply of CXCL11 by way of a vaccinia virus, however not by modified T cells, enhances the efficacy of adoptive T cell remedy and vaccines. Oncoimmunology. 2018;7:e1395997.
Rosewell Shaw A, Porter CE, Watanabe N, Tanoue Ok, Sikora A, Gottschalk S, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells towards metastatic head and neck most cancers. Mol Ther. 2017;25:2440–51.
Chiou VL, Burotto M. Pseudoprogression and immune-related response in stable tumors. J Clin Oncol. 2015;33:3541–3.
